drugset / Trial / NCT00652431

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)

NCT00652431

Phase 1 Completed 18 enrolled Organon and Co Merck Sharp & Dohme LLC · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets) in healthy subjects. Treatment spans 7 days

Timeline

Start
2007-05
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Comparator Niacin Small molecule 2000 mg
Subject Simvastatin Small molecule 20 mg

Indications